Zoltán Csiki

Zoltán Csiki

Auto-generated profile, based on publicly available information

Zoltán Csiki

Department of Internal Medicine, University of Debrecen, 4032 Debrecen, Hungary

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2008
Verified
Journal Article
Closed access
CACsilla András
Csilla András
APAndrea Ponyi
Andrea Ponyi
TCTamás Constantin
Tamás Constantin
ZCZoltán Csiki
Zoltán Csiki
ESEva Szekanecz
Eva Szekanecz
KDKatalin Dankó
Katalin Dankó

4 September 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
OTOrsolya Timár
Orsolya Timár
ZSZoltán Szekanecz
Zoltán Szekanecz
KGKerekes György
Kerekes György
JVJudit Végh
Judit Végh
AOAnna V Oláh
Anna V Oláh
GSGabriella Szűcs
Gabriella Szűcs
Introduction: We studied the effect of rosuvastatin on endothelial and macrovascular function, cardiovascular risk factors and the complement pathway in patients with systemic sclerosis (SSc). Methods: Altogether 28 patients with SSc underwent laboratory and complex vascular assessments before and after six months of 20 mg rosuvastatin treatment. Flow-mediated dilation (FMD) of the brachial artery, as well as carotid artery intima-media thickness (ccIMT), carotid-femoral and aorto-femoral pulse wave-velocity (PWV) were analyzed by ECG-synchronized ultrasound. Ankle-brachial index (ABI) was determined by Doppler, and forearm skin microcirculation was assessed by Laser Doppler perfusion monitoring. Results: Brachial artery FMD significantly improved upon rosuvastatin therapy (2.2% ± 3.3% before versus 5.7% ± 3.9% after treatment, P = 0.0002). With regard to patient subsets, FMD significantly improved in the 21 lcSSc patients (from 2.1% to 5.6%, P = 0.001). In the seven dcSSc patients, we observed a tendency of improvement in FMD (from 3% to 6%, P = 0.25). Changes in PWV, ccIMT and ABI were not significant. Mean triglyceride (1.7 ± 0.97 versus 1.3 ± 0.46 mmol/l, P = 0.0004), total cholesterol (5.3 ± 1.6 mmol/l versus 4.2 ± 1.3 mmol/l, P = 0.0003), low density lipoprotein cholesterol (3.0 ± 1.3 versus 2.2 ± 1.0 mmol/l, P = 0.005) and C-reactive protein levels (CRP) (5.1 ± 5.2 versus 3.4 ± 2.7, P = 0.01) levels significantly decreased after rosuvastatin treatment. Mean C3, C4 and IC levels also decreased significantly as compared to pretreatment values. Conclusions: Six-month rosuvastatin therapy improves endothelial function and lowers CRP, C3, C4 and IC levels indicating possible favourable effects of this statin on the cardiovascular and immune system in SSc.

Verified
Journal Article
Open access
PDF file
KZKatalin S. Zsóri
Katalin S. Zsóri
LMLászló Muszbek
László Muszbek
ZCZoltán Csiki
Zoltán Csiki
ASAmir Shemirani
Amir Shemirani
RT-qPCR is the standard method for studying changes in relative transcript level in different experimental and clinical conditions and in different tissues. No validated reference genes have been reported for the normalization of transcript level in platelets. The very low level of platelet RNA and the elimination of leukocyte contamination represented special methodological difficulties. Our aims were to apply a simple technique to separate platelets for transcript level studies, and select the most stable reference genes for platelets from healthy individuals and from patients with the history of myocardial infarction. We developed a simple, straightforward method of platelet separation for RNA isolation. Platelet activation was inhibited by using acid-citrate-dextrose for anticoagulation and by prostaglandin E1. Leukocyte contamination was eliminated by three consecutive centrifugations. Samples prepared by this method were free of leukocytes, showed no inhibition in PCR reaction and no RNA degradation. The assay demands low blood volume, which complies with the requirements of everyday laboratory routine. Seventeen potential reference genes were investigated, but eight of them were excluded during optimization. The stability of the remaining genes, EEF2, EAR, ACTB, GAPDH, ANAPC5, OAZ1, HDGF, GNAS, and CFL1, were determined by four different descriptive statistics. GAPDH, GNAS, and ACTB were shown to be the most stable genes in platelets of healthy individuals, while HDGF, GNAS, and ACTB were the most stable in platelets of patients with the history of myocardial infarction. The results confirm that data normalization needs assessment of appropriate reference genes for a particular sample set.

1 July 2011 in Microvascular Research
Verified
Journal Article
Closed access
ZCZoltan Csiki
Zoltan Csiki
IGIldiko Garai
Ildiko Garai
ASAmir H. Shemirani
Amir H. Shemirani
GPGabor Papp
Gabor Papp
KZKatalin S. Zsori
Katalin S. Zsori
MZMargit Zeher
Margit Zeher

1 January 2011 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
ASAmir Shemirani
Amir Shemirani
ESEdit Szomják
Edit Szomják
EBEmese Balogh
Emese Balogh
CACsilla András
Csilla András
DKDóra Kovács
Dóra Kovács
ZCZoltán Csiki
Zoltán Csiki
Patients with primary Raynaud's phenomenon may have a genetically determined risk for clotting factors that predispose them to aberrant microvascular thrombosis. We investigated the prevalence of factor V substitution of G to A at position 1691 (FVLeiden), prothrombin G20210A, and methyltetrahydrofolate reductase C677T mutations in these patients. Two hundred (158 women, 42 men, mean age of 42.4 ± 13.7 years) consecutive patients with primary Raynaud's phenomenon and 200 age-sex-matched healthy controls of Hungarian origin were included in a case–control study. The prevalence of methyltetrahydrofolate reductase C677T homozygous among patients was significantly lower than in the control group (odds ratio 0.4, 95% confidence interval 0.2–0.9, P < 0.05). The prevalence of other thrombosis-associated alleles did not differ between patients with primary Raynaud's phenomenon and control subjects. FVLeiden, prothrombin G20210A, and polymorphism, prothrombin G20210A mutations have no apparent effect on the etiology of primary Raynaud's phenomenon.

14 August 2013 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
CACsilla András
Csilla András
LTLászló Tóth
László Tóth
JPJános Pósán
János Pósán
ECEmese Csiki
Emese Csiki
MTMiklós Tanyi
Miklós Tanyi
ZHZsolt Horváth
Zsolt Horváth
Secondary bladder neoplasms are uncommon and they represent only 2% of all malignant bladder tumors.